The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Nanoparticles for drug delivery in cancer treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Protein—surface interactions in the presence of polyethylene oxide
Jeon, S. I., Lee, J. H., Andrade, J. D., & De Gennes, P. G. (1991) · Journal of Colloid and Interface Science · doi:10.1016/0021-9797(91)90043-8 · Cited by 1,523
Targeted drug delivery via the folate receptor
Sudimack, J., & Lee, R. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00062-9 · Cited by 1,474
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Kukowska-Latallo, J. F., Candido, K. A., Cao, Z., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., Balogh, L. P., Khan, M. K., & Baker, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3921 · Cited by 912
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
Storm, G., Belliot, S. O., Daemen, T., & Lasic, D. D. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00039-a · Cited by 877
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Nanostructure-mediated drug delivery
Hughes, G. A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2004.11.009 · Cited by 561
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
p H-Sensitive Liposomes: Possible Clinical Implications
Yatvin, M. B., Kreutz, W., Horwitz, B. A., & Shinitzky, M. (1980) · Science · doi:10.1126/science.7434025 · Cited by 415
Stewart, S., Jablonowski, H., Goebel, F. D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J., & Dezube, B. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.683 · Cited by 358
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327
Targeted Drug Delivery in Cancer Therapy
Vasir, J. K., & Labhasetwar, V. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400405 · Cited by 327
Doxorubicin in sterically stabilized liposomes
Lasic, D. D. (1996) · Nature · doi:10.1038/380561a0 · Cited by 308
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Control of tumour vascular permeability
Baban, D. F., & Seymour, L. W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00003-9 · Cited by 237
Koukourakis, M. I., Giatromanolaki, A. N., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., & Sage, E. H. (2003) · PubMed · Cited by 220
High affinity binding of paclitaxel to human serum albumin
Paál, K., Müller, J., & Hegedûs, L. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02107.x · Cited by 191
Interaction of taxol with human serum albumin
Purcell, M., Neault, J. F., & Tajmir-Riahi, H. A. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00251-4 · Cited by 189
Huang, S. K., Stauffer, P. R., Hong, K., Guo, J., Phillips, T. L., Huang, A., & Papahadjopoulos, D. (1994) · PubMed · Cited by 183
Vascularization of tumors: A review
Shubik, P. (1982) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00409698 · Cited by 179
Microcirculation of tumors Part I: Anatomy, function, and necrosis
Rubin, P., & Casarett, G. W. (1966) · Clinical Radiology · doi:10.1016/s0009-9260(66)80027-2 · Cited by 147
San Antonio Breast Cancer Symposium
Fricker, J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70329-2 · Cited by 142
Transvascular drug delivery in solid tumors
Fan, Y. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80042-8 · Cited by 132
San Antonio Breast Cancer Symposium 2016
Gourd, K. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30658-1 · Cited by 89
Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs
Brown, R. E., & Links, M. J. (1999) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399499001099x · Cited by 85
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
Jones, A., & Harris, A. L. (1998) · PubMed · Cited by 83
Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Hattori, Y., & Maitani, Y. (2005) · Current Drug Delivery · doi:10.2174/1567201054368002 · Cited by 60
Cited by
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Metadata
- Authors
- Haley, B., & Frenkel, E.
- Venue
- Urologic Oncology: Seminars and Original Investigations
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 26
- Issue
- 1
- Pages
- 57-64
- ISSN
- 1078-1439 (ISSN-L)
- OpenAlex
- W2039793277
- Cited by
- 791
- References
- 44
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.